A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil

CHIH-HUNG HSUANN-LII CHENGCHIUN HSUCHIH-HSIN YANGYEN-SHEN LUCHIA-CHI LINBu C.-F.KUN-HUEI YEH2020-04-282020-04-2820020250-7005https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036875569&partnerID=40&md5=ad65683573bfe5b2b1e3b020523b2461https://scholars.lib.ntu.edu.tw/handle/123456789/487373[SDGs]SDG3A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouraciljournal article125529662-s2.0-0036875569